VERAXA Biotech (NASDAQ: VRXA) Building A New Approach To Precision Cancer Therapy

VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities. Its proprietary BiTAC platform uses two complementary molecules that are designed to activate cytotoxic activity only when both recognize targets on the same tumor cell. The company is applying the BiTAC concept to both antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with an emphasis on solid tumors. With ADCs and bispecific antibodies attracting substantial investment, VERAXA is operating in oncology markets where technological differentiation can have significant strategic value.

VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a time when oncology research is increasingly focused on a difficult question: how can powerful treatments be made more selective without sacrificing their ability to kill cancer cells? The wiss biotechnology company is approaching that problem through a portfolio of antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”) and engineered antibody formats. At the center of the strategy is its proprietary BiTAC, or Bi-targeted Tumor-Associated Cytotoxicity, concept.

The objective is not simply to produce another antibody with a new target. VERAXA is attempting to change the...

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

The latest news and updates relating to VRXA are available in the company's newsroom at

Corporate Communications

IBN

Austin, Texas

512.354.7000 Office

[email protected]

IBN

[email protected]

MENAFN16092026005728012573ID1111675124